On March 8, 2022 Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, reported plans to present new data for multiple research programs across its portfolio of cis-targeted immunotherapies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in New Orleans, Louisiana, April 8-13, 2022 (Press release, Asher Biotherapeutics, MAR 8, 2022, View Source [SID1234609709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations provide additional data supporting the best-in-class potential of AB248, Asher Bio’s CD8-targeted IL-2 immunotherapy, and further validate the company’s cis-targeting platform, demonstrating its ability to rapidly generate highly selective molecules that target multiple immunomodulators to a diverse set of immune cell types. Asher Bio expects to file an investigational new drug application for AB248, its CD8-targeted IL-2 immunotherapy, in the third quarter of 2022 and for AB821, its CD8-targeted IL-21 immunotherapy, in the second half of 2023.

Details of the poster presentations are as follows:

Presentation Title: AB248 is a CD8+ T cell selective IL-2 designed for superior safety and anti-tumor efficacy
Session Title: Immunomodulatory Agents and Interventions 2
Session Date & Time: Tuesday, April 12, 2022 from 1:30 p.m. – 5:00 p.m. CT (11:30 a.m. – 3:00 p.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 3518

Title: Selective activation of CD8+ T cells by a CD8-targeted IL-21 results in enhanced anti-tumor efficacy and safety
Session Title: Therapeutic Antibodies 1
Session Date & Time: Tuesday, April 12, 2022 from 9:00 a.m. – 12:30 p.m. CT (7:00 a.m. – 10:30 a.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 2882

Title: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy
Session Title: Adoptive Cell Therapy 1
Session Date & Time: Sunday, April 10, 2022 from 1:30 p.m. – 5:00 p.m. CT (11:30 a.m. – 3:00 p.m. PT)
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Abstract Number: 561

The abstracts are now available on the AACR (Free AACR Whitepaper) conference website.